| Essential thrombocythemia | |
|---|---|
| Other names | Essential thrombocythaemia, essential thrombocytosis, primary thrombocytosis |
.jpg) | |
| Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia. | |
| Specialty | Hematology  |
| Symptoms | Fatigue, insomnia, migraines, headache, and dizziness.[1] |
| Complications | Thrombosis, transient ischemic attack, acute coronary syndrome, Budd-Chiari syndrome.[1] |
| Causes | Overproduction of hematopoietic cells, genetic mutations.[1] |
| Diagnostic method | Clinical criteria. |
| Differential diagnosis | Chronic myelogenous leukemia, myelodysplastic syndrome, polycythemia vera, primary myelofibrosis, secondary thrombocytosis.[1] |
| Treatment | Low-dose aspirin, plateletpheresis, cytoreductive therapy.[1] |
| Prognosis | Median survival is 18 years.[1] |
| Frequency | 0.6-2.5/100,000 cases per year.[2] |
In hematology, essential thrombocythemia (ET) is a rare chronic blood cancer (myeloproliferative neoplasm) characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow.[3] It may, albeit rarely, develop into acute myeloid leukemia or myelofibrosis.[3] It is one of the blood cancers wherein the bone marrow produces too many white or red blood cells, or platelets.[3]
- ^ a b c d e f Ashorobi, Damilola; Gohari, Pouyan (August 6, 2023). Essential Thrombocytosis. Treasure Island (FL): StatPearls Publishing. PMID 30969531 – via PubMed.
- ^ Cite error: The named reference
emergwas invoked but never defined (see the help page). - ^ a b c Beer, PA; Green, AR (2009). "Pathogenesis and management of essential thrombocythemia". Hematology. 2009: 621–628. doi:10.1182/asheducation-2009.1.621. PMID 20008247.